DelveInsight’s report titled “Fragile X Syndrome Pipeline Insight 2023” offers extensive information on more than 20+ companies and over 22+ pipeline drugs in the field of Fragile X Syndrome research. The Fragile X Syndrome pipeline report encompasses detailed profiles of the pipeline drugs for Fragile X Syndrome, including information on Fragile X Syndrome clinical trials and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.
For the Fragile X Syndrome emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Fragile X Syndrome pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, Fragile X Syndrome clinical trial studies conducted for Fragile X Syndrome, any NDA approvals obtained for Fragile X Syndrome, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.
To explore more information on the latest breakthroughs in the Fragile X Syndrome Pipeline treatment landscape of the report, click here @ Fragile X Syndrome Pipeline Outlook
Key Takeaways from the Fragile X Syndrome Pipeline Report
- DelveInsight’s Fragile X Syndrome Pipeline analysis depicts a robust space with 20+ active players working to develop 22+ pipeline treatment therapies.
- The leading Fragile X Syndrome Companies are working in the market include Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics Inc, Marinus Pharmaceuticals, Novartis Pharmaceuticals, Neuren Pharmaceuticals, Hoffmann-La Roche, Healx, Nova Mentis, Lysogene, Actinogen, Prilenia Therapeutics, Confluence Pharmaceuticals, Sentinel Oncology, and others
- Promising Fragile X Syndrome Pipeline Therapies in the various stages of development include BPN14770/ zatolmilast, ZYN002 – transdermal gel, ZYN002 – transdermal gel, arbaclofen, zatolmilast, and others.
- Zynerba Pharmaceuticals announced that the US Food and Drug Association has granted orphan-drug designation to ZYN002 cannabidiol (CBD) gel, for the treatment of Fragile X syndrome (FXS).
- Tetra’s investigational new drug, named BPN14770, can selectively target and inhibit, or suppress, only the PDE4D enzyme. PDE4D plays an important role in cognition. A recent study of over a million healthy human subjects showed connections between genetic variants in PDE4D and years of educational attainment and performance on cognitive tests. Tetra Therapeutics’s BPN14770 targets only PDE4D, and only at specific times of cellular activity. BPN14770 is designed to modulate, rather than completely inhibit, PDE4D. The desired result from clinical trial testing is two-fold: that Tetra’s BPN14770 will improve cognitive function by prolonging cAMP activity, while safety and tolerability are improved because the enzyme is not completely inhibited. Currently it is being investigated in Phase III stage of development.
- Zygel is the first and only pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. Zygel is being developed for patients suffering from FXS, ASD in pediatric patients, 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE). Zynerba Pharmaceuticals is conducting phase III clinical trials for the treatment of Fragile X Syndrome.
Fragile X Syndrome Overview
Fragile X syndrome (FXS) is a genetic disorder. FXS is caused by changes in a gene that scientists called the fragile X mental retardation 1 (FMR1) gene when it was first discovered. The FMR1 gene usually makes a protein called fragile X mental retardation protein (FMRP).
For further information, refer to the detailed Fragile X Syndrome Unmet Needs, Fragile X Syndrome Market Drivers, and Market Barriers, click here for Fragile X Syndrome Ongoing Clinical Trial Analysis
Fragile X Syndrome Emerging Drugs Profile
- Zatolmilast: Tetra Discovery Partners
- Zygel: Zynerba Pharmaceuticals
- Pridopidine: Prilenia Therapeutics
Fragile X Syndrome Pipeline Therapeutics Assessment
There are approx. 20+ Fragile X Syndrome companies which are developing the therapies for Fragile X Syndrome. The Fragile X Syndrome companies which have their Fragile X Syndrome drug candidates in the most advanced stage, i.e. Phase III include Zynerba Pharmaceuticals and others.
Request a sample and discover the recent advances in Fragile X Syndrome Ongoing Clinical Trial Analysis and Medications, click here @ Fragile X Syndrome Treatment Landscape
Fragile X Syndrome Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Fragile X Syndrome Therapeutics Market include-
Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics Inc, Marinus Pharmaceuticals, Novartis Pharmaceuticals, Neuren Pharmaceuticals, Hoffmann-La Roche, Healx, Nova Mentis, Lysogene, Actinogen, Prilenia Therapeutics, Confluence Pharmaceuticals, Sentinel Oncology, and others.
Dive deep into rich insights for drugs for Fragile X Syndrome Pipeline, click here @ Fragile X Syndrome Unmet Needs and Analyst Views
Scope of the Fragile X Syndrome Pipeline Report
- Coverage- Global
- Fragile X Syndrome Companies- Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics Inc, Marinus Pharmaceuticals, Novartis Pharmaceuticals, Neuren Pharmaceuticals, Hoffmann-La Roche, Healx, Nova Mentis, Lysogene, Actinogen, Prilenia Therapeutics, Confluence Pharmaceuticals, Sentinel Oncology, and others.
- Fragile X Syndrome Pipeline Therapies- BPN14770/ zatolmilast, ZYN002 – transdermal gel, ZYN002 – transdermal gel, arbaclofen, zatolmilast, and others.
- Fragile X Syndrome Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Fragile X Syndrome Mergers and acquisitions, Fragile X Syndrome Licensing Activities @ Fragile X Syndrome Emerging Drugs, and Recent Trends
Table of Content
- Introduction
- Fragile X Syndrome Executive Summary
- Fragile X Syndrome: Overview
- Fragile X Syndrome Pipeline Therapeutics
- Fragile X Syndrome Therapeutic Assessment
- Fragile X Syndrome– DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Fragile X Syndrome Collaboration Deals
- Late Stage Products (Phase III)
- Zatolmilast: Tetra Discovery Partners
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- HLX-0201: Healx
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Pridopidine: Prilenia Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Fragile X Syndrome Key Companies
- Fragile X Syndrome Key Products
- Fragile X Syndrome- Unmet Needs
- Fragile X Syndrome- Market Drivers and Barriers
- Fragile X Syndrome- Future Perspectives and Conclusion
- Fragile X Syndrome Analyst Views
- Fragile X Syndrome Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services